+61 (03) 9482 3940 157 Heidelberg Rd, Northcote, VIC 3070 www.renerve.com.au ASX Announcement 19 October 2026 Positive 12-month preclinical data for NervAlign® Nerve Guide Matrix Key Highlights • 12-month preclinical sheep data show strong nerve regeneration and return of nerve function across...
Positive 12-Month Data for NervAlign Nerve Guide Matrix
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The study showed that animals treated with the NervAlign matrix exhibited similar walking ability and nerve function recovery compared to those treated with an autologous nerve graft. Preliminary analysis indicated successful regrowth of blood vessels and nerve fibers, with further assessments planned for additional animals. The company is optimistic about these results, which suggest that the NervAlign matrix could serve as a viable alternative to traditional nerve grafting techniques.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Story so far
Earlier from Renerve
- Positive FDA Feedback on NervAlign Nerve Guide Matrix
- ReNerve AGM Presentation
- ReNerve completes first cases in Hong Kong and Malaysia
- ReNerve and RMIT awarded $499k grant
- ReNerve Secures Marketing Approval in India
Follow Renerve into a list and get an email when it puts out news.
Follow Renerve